Enanta Pharmaceuticals, Inc.
Financials
Valuation Metrics
Enanta Pharmaceuticals, Inc.'s Market Cap is $302M. At end of 2025 it was $337M. Ranked #2873 of 3,116 in US market (top 92%), #1287 of 1,470 on NASDAQ (top 88%), #229 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 86%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $302M | US#2,873/3,116 Sec#229/265 |
| Revenue | $65M | US#2,725/3,116 Sec#140/265 |
| Net Income | $-63M | US—/3,116 Sec—/265 |
| Total Assets | $297M | US#2,908/3,116 Sec#208/265 |
| Net Assets | $101M | US#2,798/3,116 Sec#214/265 |
| Employees | 120 | US#2,584/3,116 Sec#164/265 |
| Value | ||
| P/B | 2.99x | US#1,900/3,116 Sec#104/265 |
| P/S | 4.63x | US#2,330/3,116 Sec#82/265 |
| FCF Yield | -12.21% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -62.56% | US#2,721/3,116 Sec#179/265 |
| ROA | -21.30% | US#2,807/3,116 Sec#134/265 |
| Op. Margin | -89.99% | US#2,707/3,116 Sec#121/265 |
| Revenue Growth | 0.70% | US#2,147/3,116 Sec#130/265 |
| Financial Health | ||
| Debt Ratio | 193.73% | US#1,758/3,116 Sec#198/265 |
| Total Debt | $56M | US#2,594/3,116 Sec#150/265 |
| FCF | $-37M | US#2,494/3,116 Sec#107/265 |
| Cash | $33M | US#2,723/3,116 Sec#244/265 |
| Current Ratio | 3.76x | US#617/3,116 Sec#167/265 |
| Performance | ||
| 1Y Return | -5.11% | US#1,569/3,116 Sec#139/265 |
| 1M Return | -19.75% | US#1,922/3,116 Sec#118/265 |
| From 52W High | -39.36% | US#2,046/3,116 Sec#133/265 |
| 1Y MDD | -38.28% | US#1,607/3,116 Sec#87/265 |
| Trading | ||
| Volume | 286,942 shares | US#2,719/3,116 Sec#254/265 |
| Trading Value | $3M | US#2,896/3,116 Sec#249/265 |
| Per Share | ||
| EPS | $-2.17 | US—/3,116 Sec—/265 |
| BPS | $3.48 | US#2,418/3,116 Sec#153/265 |
Company Info
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.